Healthcare Industry News: Kyphon
News Release - August 1, 2006
Dr. Tony Chou Joins The Vertical GroupSUMMIT, N.J., Aug. 1 (HSMN NewsFeed) -- The Vertical Group, a leading medical technology venture capital firm, announced today that Tony Chou, M.D. has joined the firm as a venture partner in its Palo Alto office. Dr. Chou is an interventional cardiologist and formerly Vice President and General Manager of Abbott Vascular, a division of Abbott Laboratories. Jack Lasersohn, a general partner of The Vertical Group said, "We are delighted that Dr. Chou is joining our team on the West Coast. His clinical and industry experience will further enhance our ability to participate in healthcare investment opportunities and add significant value to many of our portfolio companies."
The Vertical Group is one of the largest venture capital firms in the United States focused on medical devices and biotechnology. The firm and its partners have founded or led investments in many of the most successful venture-backed medical device companies of the past two decades including: SciMed Life Systems, Kyphon Inc., ev3 Inc., CardioThoracic Systems, Support Systems International, E.P. Technologies, Cardiovascular Imaging Systems, Ventana Medical Systems, Integrated Vascular Systems, Spinecore, Optos, Osteobiologics, and Masimo Corporation. The Vertical Group also has been an active and successful investor in medical device companies involved in corporate buyout and spin-off transactions including Xomed Surgical Products, American Medical Systems, Wright Medical Group, and Tornier.
Headquartered in Summit, NJ, The Vertical Group has been an independent firm since 1988. The firm's principals include five general partners: Stephen D. Baksa, Richard B. Emmitt, Yue-Teh Jang, Jack W. Lasersohn, and John E. Runnells; and two special limited partners: Edward M. Giles, former President of F. Eberstadt & Co., Inc. and Patrick R.D. Paul, founder and former CEO of Support Systems International.
Source: The Vertical Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.